U.S. markets open in 8 hours 59 minutes
  • S&P Futures

    4,007.00
    +3.75 (+0.09%)
     
  • Dow Futures

    34,023.00
    +37.00 (+0.11%)
     
  • Nasdaq Futures

    11,808.25
    +2.50 (+0.02%)
     
  • Russell 2000 Futures

    1,844.10
    +2.20 (+0.12%)
     
  • Crude Oil

    77.35
    +0.42 (+0.55%)
     
  • Gold

    1,784.80
    +3.50 (+0.20%)
     
  • Silver

    22.55
    +0.13 (+0.59%)
     
  • EUR/USD

    1.0490
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    3.5990
    0.0000 (0.00%)
     
  • Vix

    20.75
    +1.69 (+8.87%)
     
  • GBP/USD

    1.2186
    -0.0008 (-0.06%)
     
  • USD/JPY

    136.9970
    +0.3120 (+0.23%)
     
  • BTC-USD

    17,012.63
    -320.07 (-1.85%)
     
  • CMC Crypto 200

    401.82
    -9.40 (-2.29%)
     
  • FTSE 100

    7,567.54
    +11.31 (+0.15%)
     
  • Nikkei 225

    27,908.60
    +88.20 (+0.32%)
     

Forma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease Study

  • Forma Therapeutics Holdings Inc (NASDAQ: FMTX) has presented blinded data on sickle cell disease patients who received 600 mg of FT-4202, a pyruvate kinase R activator.

  • The 600 mg high-dose cohort featured fewer hemoglobin responders than the 300-mg arm, but FT-4202 showed a similar safety and tolerability profile as the 300 mg cohort, despite the doubling of the dose.

  • Six of the seven patients who received the 300-mg dose of FT-4202 had hemoglobin increases of 1.0 g/dl or greater from baseline.

  • Four of the seven patients taking 600 mg had hemoglobin increases of 1.0 g/dl or greater from baseline.

  • The 600 mg dose fared numerically worse on other endpoints, too, lowering LDH in four patients compared to the six people positively affected by the 300 mg dose.

  • The median change in LDH and reticulocytes, respectively hematologic and hemolytic biomarkers, was also numerically lower at 600 mg.

  • Forma will conduct an open-label extension study giving a 400-mg dose for 12 weeks.

  • Forma is also using a 400-mg dose and a 200-mg dose in its Phase 2/3 clinical trial. The primary endpoints of phase 2/3 are hemoglobin response at Week 24 and vaso-occlusive crisis rate across the 52-week blinded treatment period.

  • Unblinded 600 mg cohort data will be reported at an upcoming medical conference in Summer 2021, in addition to initial results from the ongoing open-label extension.

  • Price Action: FMTX shares are trading 8.1% lower at $23.13 in market hours on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.